Skip to main content
    E

    Estrella Immunopharma Inc. (ESLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.38
    -0.13 (-26.07%)

    Market Cap: $22.36M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Estrella Immunopharma Inc. (ESLA) Financials: Revenue, Profit and Cash Flow

    Updated Aug 13, 2026. Financial statements from company filings, amounts in US dollars.

    Estrella Immunopharma reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$13.06M, operating cash flow was -$1.79M and free cash flow was -$1.79M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$2.31M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $13.06M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024N/AN/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Research and development$10.25M$6.41M$4.11M$10.45M$1.39M$457.23K
    Operating income-$13.06M-$8.85M-$7.31M-$11.11M-$1.69M-$733.69K
    Net income-$13.06M-$8.85M-$7.31M-$11.11M-$1.69M-$733.69K
    EBITDA-$13.06M-$8.85M-$7.31M-$11.11M-$1.69M-$733.69K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating income-$2.08M-$2.29M-$613.20K-$4.80M-$5.54M-$2.10M-$1.05M-$3.38M-$3.95M-$469.53K-$1.02M-$1.87M
    Net income-$2.31M-$2.29M-$613.17K-$4.80M-$5.54M-$2.10M-$1.05M-$3.38M-$3.95M-$469.53K-$1.02M-$1.87M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $1.38M were 43.4% of total assets of $3.18M, against total liabilities of $13.54M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$3.18M$3.14M$4.45M$9.99M$4.92M$0
    Current assets$1.68M$1.64M$4.45M$52.43K$4.92M$0
    Cash and equivalents$1.38M$916.92K$4.17M$40.80K$4.09M$0
    Total liabilities$13.54M$3.00M$180.70K$2.92M$5.96M$0
    Short-term debtN/AN/AN/A$498.60KN/AN/A
    Shareholder equity-$10.37M$143.73K$4.27M$7.07M-$1.04M$0
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$1.82M$3.66M$3.18M$3.52M$2.98M$2.44M$3.14M$3.74M$4.45M$8.63M$9.45M$27.35M
    Total liabilities$9.26M$8.93M$13.54M$13.36M$9.08M$4.28M$3.00M$2.99M$180.70K$138.49K$398.73K$17.28M
    Cash and equivalents$146.67K$1.93M$1.38M$1.63M$1.32M$421.47K$916.92K$1.80M$4.17M$4.73M$9.05M$22.14M
    Shareholder equity-$7.43M-$5.27M-$10.37M-$9.84M-$6.09M-$1.83M$143.73K$746.29K$4.27M$8.49M$9.05M$10.07M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$1.79M-$3.11M-$16.07M-$1.04M-$1.44M-$670.82K
    Capital expenditures$0$4$0$0$0$0
    Free cash flow-$1.79M-$3.11M-$16.07M-$1.04M-$1.44M-$670.82K
    Investing cash flowN/A$4.96MN/A$36.17M-$45.19M-$273.07K
    Financing cash flow$2.25M-$134.99K$12.79M-$35.56M$5.53M$670.82K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$1.78M-$6.70M-$177.49K-$727.33K-$414.88K-$465.98K-$896.07K-$2.22M-$291.51K-$15.78M-$11.27M-$275.72K
    Capital expenditures$0$0$0$0$0$0$4$3$3$3$0$0
    Free cash flow-$1.78M-$6.70M-$177.49K-$727.33K-$414.88K-$465.98K-$896.07K-$2.22M-$291.52K-$15.78M-$11.27M-$275.72K
    Last 12 quarters

    Frequently Asked Questions About ESLA

    What is Estrella Immunopharma's annual revenue?

    Estrella Immunopharma reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Estrella Immunopharma profitable?

    No. Estrella Immunopharma reported net income of -$13.06M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does ESLA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$1.79M minus capital expenditures of $0 produced free cash flow of -$1.79M.

    How much debt does Estrella Immunopharma have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $1.38M.